Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy [3]

AIDS

Volumn 16, Issue 14, 2002, Pages 1983-1984

  Costa, Asuncion ^a   Pulido, Federico ^a   Rubio, Rafael ^a   Cepeda, Concepcion ^a   Torralba, Miguel ^a   Costa, Jos R ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CHOLESTEROL; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; RITONAVIR; TRIACYLGLYCEROL;

ADULT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LETTER; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LIPID METABOLISM; MALE; VIRAL LOAD;

EID: 0037183912     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209270-00025     Document Type: Letter

References (8)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
2. Smith JH, Martin GJ, Decker CF. Hyperlipidemia associated with the use of protease inbibitors. Clin Infect Dis 2000, 31:207-208.
3. Scott T, Garris C, Rogers M, Graham N, Garrett L, Pedneault L. Safety profile and tolerability of amprenavir in patients enrolled in an early access program. Clin Ther 2001, 23:252-259.
4. Amprenavir, package insert; February 2002.
5. Haubrich R, Thompson M, Schooley R, et al. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS 1999, 13:2411-2420.
6. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis 1999, 179:808-816.
7. Duval X, Lamotte C, Race E, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother 2002, 46:570-574.
8. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inbibitors. The Swiss Cohort Study. Circulation 1999, 100:700-705.